A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

Inclusion Criteria: * Written informed consent by and HIPAA authorization for release of personal health information obtained from the research participant. * Able to speak and read English to a sufficient level of fluency to provide informed consent and complete the study questionnaires. * Age ≥ 18 years at the time of consent. * ECOG Performance Status of ≤ 3 within 28 days prior to consent. * Histological or cytologically confirmed urothelial carcinoma. * Patients must be planned to start systemic therapy with enfortumab vedotin * At time of enrollment, patients must be planned to start enfortumab with or without pembrolizumab Exclusion Criteria: Subjects meeting any of the criteria below may not participate in the study: * Inability of the subject to understand and comply with study procedures. * Having previously received enfortumab vedotin * Students/employees of the study institution, pregnant women, prisoners, and institutionalized individuals (to prevent enrollment of vulnerable subjects).